Skip to main content
eScholarship
Open Access Publications from the University of California

Safe and Effective Prophylaxis with Bi-Monthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population

  • Author(s): Levy, ER
  • Musick, L
  • Zinter, MS
  • Lang, T
  • Cowan, MJ
  • Weintrub, PS
  • Dvorak, CC
  • et al.

Published Web Location

http://10.0.4.73/INF.0000000000000946
No data is associated with this publication.
Abstract

© 2015 Wolters Kluwer Health, Inc. All rights reserved. BACKGROUND:: Without prophylaxis, Pneumocystis jiroveci pneumonia (PCP) develops in 5-15% of pediatric hematopoietic stem cell transplant (HCT) patients with mortality above 50%. Trimethoprim-sulfamethoxazole (TMP-SMZ) is standard PCP prophylaxis; pentamidine is frequently used as second-line prophylaxis due to TMP-SMZ’s potential for cytopenias. Monthly IV pentamidine has variable efficacy with PCP infection rates of 0-10% in pediatric patients, and higher breakthrough rates in those <2 years old. We hypothesized that bi-monthly (twice monthly) pentamidine might have equivalent safety and improved efficacy; therefore, we conducted a retrospective analysis of bi-monthly pentamidine PCP prophylaxis. METHODS:: We retrospectively reviewed records of all pediatric HCT patients who received bi-monthly IV pentamidine between December 2006-June 2013 and collected data regarding demographics, clinical course, prophylaxis rationale, laboratory values, and adverse events. RESULTS:: Between December 2006 and June 2013, 111 pediatric HCT patients received bi-monthly IV pentamidine (574 doses, 8758 patient-days); 31 patients were under 2 years old at initiation. In the majority (53% of courses) pentamidine was initiated because of cytopenias. Fourteen patients (12.6% of patients, 2.4% of doses) experienced a side effect prompting discontinuation; including 3 patients with infusion-related hypotension/anaphylaxis and 3 with acute pancreatic dysfunction. No patients (0%, [CI 0-3.2%] developed PCP during or following bi-monthly IV pentamidine prophylaxis. CONCLUSIONS:: Bi-monthly IV pentamidine for PCP prophylaxis in the HCT pediatric population has comparable safety to monthly IV pentamidine and was highly effective, including in the very young. Bi-monthly IV Pentamidine should be considered in pediatric patients as second line PCP prophylaxis.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item